Free Trial
NASDAQ:ALVO

Alvotech (ALVO) Stock Price, News & Analysis

Alvotech logo
$8.32 -0.18 (-2.09%)
As of 12:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Alvotech Stock (NASDAQ:ALVO)

Key Stats

Today's Range
$7.77
$8.70
50-Day Range
$8.50
$13.06
52-Week Range
$7.77
$14.76
Volume
126,056 shs
Average Volume
136,556 shs
Market Capitalization
$2.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Remove Ads

Alvotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

ALVO MarketRank™: 

Alvotech scored higher than 32% of companies evaluated by MarketBeat, and ranked 727th out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alvotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alvotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about Alvotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Alvotech are expected to grow in the coming year, from ($0.07) to $0.20 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alvotech is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alvotech is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Alvotech's valuation and earnings.
  • Percentage of Shares Shorted

    0.51% of the float of Alvotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Alvotech has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alvotech has recently increased by 7.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Alvotech does not currently pay a dividend.

  • Dividend Growth

    Alvotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.51% of the float of Alvotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Alvotech has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alvotech has recently increased by 7.15%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Alvotech has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Alvotech this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for ALVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
Receive ALVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alvotech and its competitors with MarketBeat's FREE daily newsletter.

ALVO Stock News Headlines

Alvotech (ALVO) Gets a Buy from Northland Securities
Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
Alvotech appoints Balaji Prasad as chief strategy officer
This Is a Test From GlobeNewswire
See More Headlines

ALVO Stock Analysis - Frequently Asked Questions

Alvotech's stock was trading at $13.23 at the start of the year. Since then, ALVO stock has decreased by 36.7% and is now trading at $8.3780.
View the best growth stocks for 2025 here
.

Alvotech (NASDAQ:ALVO) issued its quarterly earnings data on Wednesday, March, 26th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.50. The firm had revenue of $153.34 million for the quarter, compared to analyst estimates of $97.99 million.

Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alvotech investors own include Micron Technology (MU), Arista Networks (ANET), United Microelectronics (UMC), Weatherford International (WFRD), NVIDIA (NVDA), PACCAR (PCAR) and Axcelis Technologies (ACLS).

Company Calendar

Last Earnings
3/26/2025
Today
4/07/2025
Next Earnings (Estimated)
6/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALVO
Previous Symbol
NYSE:ALVO
Fax
N/A
Employees
1,026
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$18.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+111.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-551,730,000.00
Net Margins
-123.47%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$489.68 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$2.56 billion
Optionable
Not Optionable
Beta
-0.05
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ALVO) was last updated on 4/7/2025 by MarketBeat.com Staff
From Our Partners